Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

Stempoint Capital LP lessened its position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) by 35.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 939,369 shares of the company’s stock after selling 519,438 shares during the quarter. Stempoint Capital LP’s holdings in Whitehawk Therapeutics were worth $3,241,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quadrature Capital Ltd purchased a new position in Whitehawk Therapeutics in the fourth quarter worth about $28,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Whitehawk Therapeutics during the 1st quarter valued at about $40,000. Dimensional Fund Advisors LP bought a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $84,000. Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $159,000. Finally, Marshall Wace LLP bought a new position in shares of Whitehawk Therapeutics in the 4th quarter worth approximately $164,000. Institutional investors own 52.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on WHWK. Citizens Jmp began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 target price for the company. B. Riley Financial started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, June 25th. They issued a “buy” rating and a $10.00 price target on the stock. Weiss Ratings cut shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Oppenheimer reiterated an “outperform” rating and set a $7.00 target price on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.20.

Whitehawk Therapeutics Trading Down 0.5%

Shares of WHWK opened at $3.66 on Thursday. The company has a market capitalization of $180.99 million, a PE ratio of -2.18 and a beta of 0.77. Whitehawk Therapeutics, Inc. has a 12-month low of $1.57 and a 12-month high of $5.49. The business’s 50 day moving average is $4.17 and its 200 day moving average is $3.72.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.04. Equities research analysts predict that Whitehawk Therapeutics, Inc. will post -1.37 earnings per share for the current year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.